AM­RI fetch­es $922M in the lat­est CRO pri­vate eq­ui­ty buy­out

There’s an­oth­er pri­vate eq­ui­ty deal to re­port on from the CRO front.

Al­bany, NY-based AM­RI $AM­RI an­nounced Tues­day morn­ing that it is be­ing bought out for $922 mil­lion by The Car­lyle Group and GT­CR.

The buy­out comes at $21.75 per share, which is a weight­ed av­er­age of 60 days trad­ing ahead of the first re­ports about the brew­ing deal that first emerged on April 5th.

There have been a string of CRO buy­outs and merg­ers over the past few years, with many of these deals aimed at con­sol­i­dat­ing a glob­al­ly frac­tured in­dus­try as drug de­vel­op­ers large and small look to out­side con­trac­tors to do much of the heavy lift­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.